>>Description of the research protocol "STRIVE"

A phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs intravenous caspofungin followed by oral fluconazole step-down in the treatment of subjects with candidemia and/or invasive candidia
Phase II study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Soins Intensifs
Brugmann identifier : STRIVE
EudraCT identifier : 2015-005599-51


Involved department : Intensive care
Principal investigator : Honoré
Sponsor : CIDARA
Contact : Clinical Research Unit

>This protocol was approved by the KU Leuven ethics committee.